Saint Luke’s Health System is committed to the health and safety of our patients, visitors, and staff. Effective Nov. 1, 2021, full COVID-19 vaccination is a condition of employment for all SLHS employees.

Diuresis does not appear to play a big role in mediating the benefits of empagliflozin in heart-failure patients, according to results from a large clinical trial.

In the study, researchers examined data on more than 3,700 patients, who all had heart failure and a reduced ejection fraction, randomized to receive either empagliflozin or placebo. Overall, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased total hospitalizations for heart failure and improved health status and functional class.

Reuters Health talked to Dr. Mikhail Kosiborod, co-author of an accompanying study and cardiologist at Saint Luke's Mid America Heart Institute, about what the findings mean for patients with reduced ejection fraction and clinical practice moving forward.

Read the full Reuters Health article in M.D. alert: Diuretic effect may not mediate most empagliflozin benefits in heart-failure patients

Read more >

Related Content

Person, Hair, Nurse, Face, Female, Word
Nicole's story

"What we do is so vital. We have so much power as nurses." Nicole Roberson, Registered Nurse, Neuroscience ICU, Saint Luke's Hospital of Kansas City

Read more >
Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
Deb's story

Deb Day, Registered Nurse · Anderson County Hospital "I am a Saint Luke's Nurse.  Nurses are the lifeblood of Saint Luke’s compassionate care, and the life-changing work they do is...

Read more >
Apparel, Clothing, Coat, Lab Coat, Person, Doctor
Danielle's story

"You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse Practitioner, Saint Luke’s East Hospital

Read more >